Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. This evidence concerns the gene CD274 and thyroid gland undifferentiated (anaplastic) carcinoma.